Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...

The Food and Drug Administration restored a top vaccine regulator to his position at the agency just weeks after firing him.

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older.

The FDA's vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots from vaccine makers Novavax and Moderna.

In a memorandum following Novavax's approval in May, which narrowed the shot's label to only seniors ages 65 and older and others at-risk of severe disease, the FDA's Dr. Vinay Prasad said that he ...

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older.